MAY 22, 2021 3:23 PM PDT

Drug Combo Treats 86% of Patients with Gout

WRITTEN BY: Annie Lennon

Researchers at the University of Michigan have found that a combination of two drugs is twice as effective as current treatments to treat gout.

Gout is a form of arthritis that results from excess uric acid in the bloodstream. It causes intense joint stiffness, severe pain and swollen skin. Currently, there are few oral therapies that lower uric acid and treat gout. 

Pegloticase is a drug currently used to treat the condition. It is administered intravenously to dissolve crystallized uric acid in joints when oral medications fail. When used alone, however, it is known to create a potent antibody response in people with severe gout, limiting its efficacy. 

As such, researchers wondered whether its effects could be improved if administered alongside an immunomodulatory drug known as mycophenolate mofetil (MMF) to limit antibody production. 

"Gout can cause as severe disability as rheumatoid arthritis, but there are nowhere near the number of modalities to treat it," says Puja Khanna, one of the study’s authors. 

"Getting a new medication from inception to FDA approval can take anywhere from 10-20 years, so our team combined these drugs to optimize the efficacy of what we already have."

For the study, the researchers recruited 32 patients with gout. They were randomized on a 3:1 ratio to either receive 1000 mg of MMF twice daily or a placebo for 14 weeks. After 2 weeks of either MMF treatment or a placebo, they were all given intravenous 8 mg of Pegloticase twice a week for 12 weeks. The patients received Pegloticase alone between week 12 and week 24. 

When used alone, 42% of patients treated with Pegloticase typically see uric acid levels fall below therapeutic target levels of under 6mg/dL. Following this, 40% of control subjects in the study saw this level of improvement after 12 weeks of treatment. However, 86% of patients treated with MMF achieved this result. 

At week 24 however, the researchers noted that those with serum urate levels below 6mg/dL fell to 68% among those treated with MMF, and 30% among those treated with the placebo. As such, the researchers wonder if they had continued MMF for the whole study period, whether they would have seen a 100% response rate. 

The researchers now hope that future studies will examine how long subjects need to take MMF before and after starting Pegloticase transfusions. 

 

Sources: University of MichiganArthritis & Rheumatology

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
FEB 22, 2021
Microbiology
A Nasal Spray That Seems to Prevent the Spread of COVID-19
FEB 22, 2021
A Nasal Spray That Seems to Prevent the Spread of COVID-19
Reporting in Science, researchers have created an antiviral nasal spray that could help us get the COVID-19 pandemic und ...
FEB 18, 2021
Drug Discovery & Development
Weight-Loss Hormone Prevents Muscle-Loss
FEB 18, 2021
Weight-Loss Hormone Prevents Muscle-Loss
Scientists from the University of Southern California Leonard Davis School of Gerontology, show that a hormone known to ...
APR 05, 2021
Neuroscience
Could a Keto Diet Treat Alzheimer's Disease?
APR 05, 2021
Could a Keto Diet Treat Alzheimer's Disease?
  Researchers from Brigham Young University have found evidence that eating a ketogenic diet- which is a diet that ...
APR 13, 2021
Immunology
The "Unexpected" Reason Why COVID Antivirals Don't Work
APR 13, 2021
The "Unexpected" Reason Why COVID Antivirals Don't Work
Purdue University researchers have made a breakthrough finding that could explain why the disease is so hard to manage t ...
MAY 06, 2021
Drug Discovery & Development
Tweaked Version of Ketamine Could Solve the Opioid Crisis
MAY 06, 2021
Tweaked Version of Ketamine Could Solve the Opioid Crisis
Medications that manage post-operative pain are some of the main entry points to opioid addiction and overdose in the US ...
MAY 13, 2021
Health & Medicine
New Peptide Allows Cannabis to Fight Pain With Fewer Side Effects
MAY 13, 2021
New Peptide Allows Cannabis to Fight Pain With Fewer Side Effects
THC-rich cannabis is well known to bring relief for some chronic pain sufferers. But the downside, off putting for many ...
Loading Comments...